Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats

Nephrology Dialysis Transplantation

Volumn 26, Issue 1, 2011, Pages 92-100

  Renken, Catharina ^a   Fischer, Dagmar Christiane ^a   Kundt, Günther ^b   Gretz, Norbert ^c   Haffner, Dieter ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Akt signalling; autosomal recessive polycystic kidney disease; mTOR pathway; PCK rat; sirolimus

Indexed keywords

BILE ACID; BILIRUBIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT; CONTROLLED STUDY; DISEASE COURSE; ENZYME PHOSPHORYLATION; FEMALE; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; WEIGHT GAIN;

ANIMALS; BLOTTING, WESTERN; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; MALE; POLYCYSTIC KIDNEY DISEASES; RATS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 78349246353     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq384     Document Type: Article

References (56)

1. Bergmann C, Frank V, Kupper F et al. Diagnosis, pathogenesis, and treatment prospects in cystic kidney disease. Mol Diagn Ther 2006; 10: 163-174
2. Zerres K, Mücher G, Becker J et al. Prenatal diagnosis of autosomal recessive polycystic kidney disease (ARPKD): molecular genetics, clinical experience, and fetal morphology. Am J Med Genet 1998; 76: 137-144
3. Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med 2009; 60: 321-337
4. Turkbey B, Ocak I, Daryanani K et al. Autosomal recessive polycys-tic kidney disease and congenital hepatic fibrosis (ARPKD/CHF). Pediatr Radiol 2009; 39: 100-111
5. Bergmann C, Zerres K. Polycystic kidney disease: ADPKD and ARPKD. In: Geary DF, Schaefer F (eds.) Comprehensive Pediatric Nephrology. Philadelphia, USA: Mosby Elsevier, 2008; 155-178
6. Guay-Woodford LM, Muecher G, Hopkins SD et al. The severe perinatal form of autosomal recessive polycystic kidney disease maps to chromosome 6p21.1-p12: implications for genetic counseling. Am J Hum Genet 1995; 56: 1101-1107
7. Onuchic LF, Furu L, Nagasawa Y et al. PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats. Am J Hum Genet 2002; 70: 1305-1317
8. Ward CJ, Hogan MC, Rossetti S et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 2002; 30: 259-269
9. He QY, Liu XH, Li Q et al. G8: a novel domain associated with poly-cystic kidney disease and non-syndromic hearing loss. Bioinformatics 2006; 22: 2189-2191
10. Hiesberger T, Gourley E, Erickson A et al. Proteolytic cleavage and nuclear translocation of fibrocystin is regulated by intracellular Ca2+ and activation of protein kinase C. J Biol Chem 2006; 281: 34357-34364
11. Kaimori JY, Nagasawa Y, Menezes LF et al. Polyductin undergoes notch-like processing and regulated release from primary cilia. Hum Mol Genet 2007; 16: 942-956
12. Harris PC. Molecular basis of polycystic kidney disease: PKD1, PKD2 and PKHD1. Curr Opin Nephrol Hypertens 2002; 11: 309-314
13. Kim I, Fu Y, Hui K et al. Fibrocystin/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function. J Am Soc Nephrol 2008; 19: 455-468
14. Kim I, Li C, Liang D et al. Polycystin-2 expression is regulated by a PC2-binding domain of intracellular portion of fibrocystin. J Biol Chem 2008; 283: 31559-31566
15. Wang S, Zhang J, Nauli SM et al. Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia. Mol Cell Biol 2007; 27: 3241-3252
16. Wu Y, Dai XQ, Li Q et al. Kinesin-2 mediates physical and functional interactions between polycystin-2 and fibrocystin. Hum Mol Genet 2006; 15: 3280-3292
17. Hildebrandt F, Otto E. Cilia and centrosomes: a unifying pathogenic concept for cystic kidney disease? Nat Rev Genet 2005; 6: 928-940
18. Kolb RJ, Nauli SM. Ciliary dysfunction in polycystic kidney disease: an emerging model with polarizing potential. Front Biosci 2008; 13: 4451-4466
19. Veland IR, Awan A, Pedersen LB et al. Primary cilia and signaling pathways in mammalian development, health and disease. Nephron Physiol 2009; 111: p39-p53
20. Shillingford JM, Murcia NS, Larson CH et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogen-esis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5466-5471
21. Wahl PR, Serra AL, Le Hir M et al. Inhibition of mTOR with siro-limus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006; 21: 598-604
22. Qian Q, Du H, King BF et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 2008; 19: 631-638
23. Wahl PR, Le Hir M, Vogetseder A et al. Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease. Nephrology (Carlton, Vic) 2007; 12: 357-363
24. Walz G. Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel? Nephrol Dial Transplant 2006; 21: 1752-1757
25. Serra AL, Kistler AD, Poster D et al. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD Study. BMC Nephrol 2007; 8: 13
26. Serra AL, Kistler AD, Poster D et al. Safety and tolerability of siro-limus treatment in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2009; 24: 3334-3342
27. Fischer DC, Jacoby U, Pape L et al. Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD). Nephrol Dial Transplant 2009; 24: 1819-1827
28. Katsuyama M, Masuyama T, Komura I et al. Characterization of a novel polycystic kidney rat model with accompanying polycystic liver. Exp Anim 2000; 49: 51-55
29. Masyuk TV, Huang BQ, Ward CJ et al. Defects in cholangiocyte fi-brocystin expression and ciliary structure in the PCK rat. Gastro-enterology 2003; 125: 1303-1310
30. Masyuk TV, Huang BQ, Masyuk AI et al. Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease. Am J Pathol 2004; 165: 1719-1730
31. Muff MA, Masyuk TV, Stroope AJ et al. Development and characterization of a cholangiocyte cell line from the PCK rat, an animal model of autosomal recessive polycystic kidney disease. Lab Invest 2006; 86: 940-950
32. Lager DJ, Qian Q, Bengal RJ et al. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int 2001; 59: 126-136
33. Borges LF, Taboga SR, Gutierrez PS. Simultaneous observation of collagen and elastin in normal and pathological tissues: analysis of Sirius-red-stained sections by fluorescence microscopy. Cell Tissue Res 2005; 320: 551-552
34. Sweeney WE, von Vigier RO, Frost P et al. Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol 2008; 19: 1331-1341
35. Nagao S, Nishii K, Yoshihara D et al. Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat. Kidney Int 2008; 73: 269-277
36. Mostov KE. mTOR is out of control in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5247-5248
37. Reiling JH, Sabatini DM. Stress and mTORture signaling. Oncogene 2006; 25: 6373-6383
38. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945
39. Lee CH, Inoki K, Guan KL. mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol 2007; 47: 443-467
40. Wang X, Proud CG. The mTOR pathway in the control of protein synthesis. Physiology (Bethesda) 2006; 21: 362-369
41. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484
42. Zafar I, Belibi FA, He Z et al. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant 2009; 24: 2349-2353
43. Deters M, Nolte K, Kirchner G et al. Comparative study analyzing effects of sirolimus-cyclosporin and sirolimus-tacrolimus combinations on bile flow in the rat. Dig Dis Sci 2001; 46: 2120-2126
44. Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 2007; 82: 381-388
45. Corradetti MN, Guan KL. Upstream of the mammalian target of ra-pamycin: do all roads pass through mTOR? Oncogene 2006; 25: 6347-6360
46. Proud CG. Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem J 2007; 403: 217-234
47. Foster DA, Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle 2009; 8: 1026-1029
48. Dilling MB, Germain GS, Dudkin L et al. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 2002; 277: 13907-13917
49. Choo AY, Blenis J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 2009; 8: 567-572
50. Chaturvedi D, Gao X, Cohen MS et al. Rapamycin induces transac-tivation of the EGFR and increases cell survival. Oncogene 2009; 28: 1187-1196
51. Cybulski N, Hall MN. TOR complex 2: a signaling pathway of its own. Trends Biochem Sci 2009; 34: 620-627
52. Sarbassov DD, Guertin DA, Ali SM et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101
53. Kurmasheva RT, Huang S, Houghton PJ. Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer 2006; 95: 955-960
54. Lieberthal W, Fuhro R, Andry C et al. Rapamycin delays but does not prevent recovery from acute renal failure: role of acquired tubular resistance. Transplantation 2006; 82: 17-22
55. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009; 20: 2493-2502
56. Torres VE, Sweeney WE Jr., Wang X et al. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats. Kidney Int 2004; 66: 1766-1773